What Is the Treatment of Splenic Marginal Zone Lymphoma When Rituximab Did Not Achieve Complete Response?
This protocol applies to patients with splenic marginal zone lymphoma who received rituximab as initial therapy and did not achieve the complete response benchmarks required for that line. When first-line targets go unmet, a distinct next-step approach is indicated.
First-Line Failure — Targets Not Reached
The prior approach was rituximab alone (as preferred initial therapy), with the option of maintenance rituximab. The complete response criteria whose non-achievement triggers escalation to this protocol are:
- Resolution of organomegaly — spleen longitudinal diameter <13 cm
- Haemoglobin >12 g/dl
- Platelets >100 × 10⁹/l
- Neutrophils >1.5 × 10⁹/l
- No circulating clonal B cells on flow cytometry
- No bone marrow infiltration on immunohistochemistry
Failure to satisfy these endpoints is the condition that escalates management to the regimen below.
Next-Step Approach — Partial Overview
For patients who do not respond to rituximab, the protocol considers either an intensified systemic therapy or a surgical intervention targeting the primary disease site. The full structured regimen — covering which approach is indicated for which patient profile, and under what clinical conditions each option applies — is available via the link below.
References
DOI: 10.1016/j.annonc.2019.10.010
- For the patients who do not respond to rituximab, splenectomy [IV, B] or the addition of ChT may be considered.
- Chemoimmunotherapy is particularly indicated for fit patients with symptomatic disseminated disease, constitutional symptoms and/or signs of high-grade transformation [III, B].
- Splenectomy may be considered in selected cases, when rituximab is not indicated or ineffective [IV, B].
View source ↗